Immunestimulation in cancer patients by a new synthetic compound: BM 06 002.
A new synthetic compound 4-imino-1,3-diazobicyclo (3,1,0)-hexan-2-on (BM 06 002) has been shown in animal models to stimulate humoral and cell-mediated immune reactions. In a Phase I study in man a total absence of toxic side effects after intravenous injection of BM 06 002 has been demonstrated. In the present investigation in patients with advanced incurable cancer one single injection of this substance induced a significant stimulation of lymphocyte blastogenesis response to PHA and PWM. Delayed cutaneous hypersensitivity reactions, tested before and after drug application, were also found increased. According to thses findings BM 06 002 might be considered as an immune-stimulating compound.
D000917:Antibody Formation / Q000187:drug effects*; D000970:Antineoplastic Agents; D001943:Breast Neoplasms / Q000276:immunology; D001643:Bridged Bicyclo Compounds / Q000494:pharmacology; D005260:Female; D006588:Hexanones / Q000494:pharmacology*; D006801:Humans; D007659:Ketones / Q000494:pharmacology*; D008175:Lung Neoplasms / Q000276:immunology; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D009369:Neoplasms / Q000276:immunology*
D000970:Antineoplastic Agents; D001643:Bridged Bicyclo Compounds; D006588:Hexanones; D007659:Ketones